Cargando…

Progression-Free and Overall Survival of First-Line Treatments for Advanced Renal Cell Carcinoma: Indirect Comparison of Six Combination Regimens

SIMPLE SUMMARY: Recently, numerous treatments sharing similar mechanisms of action have been approved for advanced renal cell carcinoma. These combinations prolong survival compared to sunitinib, which was previously considered the standard of care in this context. Head-to-head comparisons between t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ossato, Andrea, Mengato, Daniele, Chiumente, Marco, Messori, Andrea, Damuzzo, Vera
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10093553/ https://www.ncbi.nlm.nih.gov/pubmed/37046690 http://dx.doi.org/10.3390/cancers15072029

Ejemplares similares

Immune checkpoint inhibitors as first line in advanced melanoma: Evaluating progression‐free survival based on reconstructed individual patient data
por: Ossato, Andrea, et al.
Publicado: (2022)

The “One-to-Many” Survival Analysis to Evaluate a New Treatment in Comparison With Therapeutic Alternatives Based on Reconstructed Patient Data: Enfortumab Vedotin Versus Standard of Care in Advanced or Metastatic Urothelial Carcinoma
por: Messori, Andrea, et al.
Publicado: (2022)

Application of the IPDfromKM-Shiny Method to Compare the Efficacy of Novel Treatments Aimed at the Same Disease Condition: A Report of 14 Analyses
por: Messori, Andrea, et al.
Publicado: (2023)

Analysis of Survival Curves: Statistical Methods Accounting for the Presence of Long-Term Survivors
por: Damuzzo, Vera, et al.
Publicado: (2019)

Survival in Patients with Relapsed-Refractory Multiple Myeloma: Indirect Comparison of Six New Treatments
por: Cancanelli, Luca, et al.
Publicado: (2023)

Axicabtagene ciloleucel in non-Hodgkin lymphoma: the restricted mean survival time as a tool for estimating progression-free life expectancy better than the median
por: Messori, Andrea, et al.
Publicado: (2020)

COVID-19 impact on skills and professional perceptions of the hospital pharmacist during the first outbreak wave
por: Damuzzo, Vera, et al.
Publicado: (2022)

Treatments for Relapsed-Refractory Diffuse Large B-cell Lymphoma: A Preliminary Evaluation of the Place in Therapy of Glofitamab, a Bispecific Monoclonal Antibody
por: Messori, Andrea, et al.
Publicado: (2022)

The Degree of Programmed Death-Ligand 1 (PD-L1) Positivity as a Determinant of Outcomes in Metastatic Triple-Negative Breast Cancer Treated With First-Line Immune Checkpoint Inhibitors
por: Di Spazio, Lorenzo, et al.
Publicado: (2022)

Efficacy of Immune Checkpoint Inhibitors in Patients with Mismatch Repair-Deficient or Microsatellite Instability-High Metastatic Colorectal Cancer: Analysis of Three Phase-II Trials
por: Cancanelli, Luca, et al.
Publicado: (2021)

SARS-COV-2 pandemic: establishing three risk levels for 19 Italian regions and two autonomous provinces
por: Messori, Andrea, et al.
Publicado: (2022)

Medical Therapy, Radiofrequency Ablation, or Cryoballoon Ablation as First-Line Treatment for Paroxysmal Atrial Fibrillation: Interpreting Efficacy Through the Shiny Method
por: Trippoli, Sabrina, et al.
Publicado: (2022)

The QOSMOS Study: Pharmacist-Led Multicentered Observational Study on Quality of Life in Multiple Sclerosis
por: Damuzzo, Vera, et al.
Publicado: (2021)

Differences in Effectiveness among Devices for Endovascular Thrombectomy in Patients with Acute Ischemic Stroke
por: Chiumente, Marco, et al.
Publicado: (2016)

CAR‐T treatment: Determining the progression‐free survival gain in patients with heavily pretreated multiple myeloma
por: Messori, Andrea
Publicado: (2020)

Burden of uterine fibroids in Italy: epidemiology, treatment outcomes, and consumption of health care resources in more than 5,000 women
por: Chiumente, Marco, et al.
Publicado: (2017)

Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer: A Systematic Review and Meta-analysis
por: Paoletti, Xavier, et al.
Publicado: (2020)

The Appropriate First-Line Chemotherapy Regimen for Incurable Pancreatic Cancer in Clinical Practice: A Consideration of Patients' Overall Survival and Quality of Life
por: Murakawa, Yasuko, et al.
Publicado: (2021)

Preparation of intravenous chemotherapy bags: evaluation of a dose banding approach in an Italian oncology hospital
por: Chiumente, Marco, et al.
Publicado: (2021)

Network Meta-analysis of Progression-Free Survival and Overall Survival in First-Line Treatment of BRAF Mutation-Positive Metastatic Melanoma
por: Amdahl, Jordan, et al.
Publicado: (2016)

Progression-free survival as a surrogate endpoint for overall survival in patients with third-line or later-line chemotherapy for advanced gastric cancer
por: Liu, Liya, et al.
Publicado: (2015)

Six MicroRNA Prognostic Models for Overall Survival of Lung Adenocarcinoma
por: Li, Juan, et al.
Publicado: (2022)

Simplified figure to present direct and indirect comparisons: Revisiting the graph 10 years later
por: Fadda, Valeria, et al.
Publicado: (2021)

First-line therapy with sunitinib in advanced renal cell carcinoma: interpretation of the overall survival data from asco 2008
por: Wood, L.
Publicado: (2009)

Is progression-free survival a more relevant endpoint than overall survival in first-line HR+/HER2− metastatic breast cancer?
por: Forsythe, Anna, et al.
Publicado: (2018)

First line immunotherapy extends brain metastasis free survival, improves overall survival, and reduces the incidence of brain metastasis in patients with advanced melanoma
por: Wang, Xuechen, et al.
Publicado: (2021)

Identification on surrogating overall survival with progression-free survival of first-line immunochemotherapy in advanced esophageal squamous cell carcinoma—an exploration of surrogate endpoint
por: Zhang, Zewei, et al.
Publicado: (2023)

Radiofrequency ablation of hepatocellular carcinoma: a meta-analysis of overall survival and recurrence-free survival
por: Gardini, Andrea Casadei, et al.
Publicado: (2018)

A retrospective study of predictive factors for unexpectedly prolonged or shortened progression-free survival and overall survival among patients with metastatic renal cell carcinoma who received first-line targeted therapy
por: Kim, Sung Han, et al.
Publicado: (2016)

Overall survival and disease-free survival in breast cancer patients treated at the Oncology Centre in Bydgoszcz – analysis of more than six years of follow-up
por: Nowikiewicz, Tomasz, et al.
Publicado: (2015)

Identification of a six-gene signature predicting overall survival for hepatocellular carcinoma
por: Liu, Gao-Min, et al.
Publicado: (2019)

Overall survival of first‐line axitinib in metastatic renal cell carcinoma: Japanese subgroup analysis from phase II study
por: Oya, Mototsugu, et al.
Publicado: (2017)

Progression-free or overall survival…revisited in BOLERO-2
por: Gupta, Sudeep
Publicado: (2014)

Synthetizing Published Evidence on Survival by Reconstruction of Patient-Level Data and Generation of a Multi-Trial Kaplan-Meier Curve
por: Messori, Andrea
Publicado: (2021)

A robust six-gene prognostic signature for prediction of both disease-free and overall survival in non-small cell lung cancer
por: Zuo, Shuguang, et al.
Publicado: (2019)

The Additional Costs per Month of Progression-Free Survival and Overall Survival: An Economic Model Comparing Everolimus with Cabozantinib, Nivolumab, and Axitinib for Second-Line Treatment of Metastatic Renal Cell Carcinoma
por: Swallow, Elyse, et al.
Publicado: (2018)

Effect of response quality and line of treatment with rituximab on overall and disease-free survival of patients with B-cell lymphoma
por: Horvat, Mateja, et al.
Publicado: (2010)

A six-gene prognostic model predicts overall survival in bladder cancer patients
por: Wang, Liwei, et al.
Publicado: (2019)

Identification of a Six-Gene Signature for Predicting the Overall Survival of Cervical Cancer Patients
por: Huo, Xiao, et al.
Publicado: (2021)

Optimization of resources by drug management: A multicentred web-administered study on the use of ipilimumab in Italy
por: Damuzzo, V, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_tcprbms20orndoqgjn3j2qkc5n